This article is more than 5 years old. Information may no longer be current.

TCT late-breaking clinical trials announced

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Cardiovascular Research Foundation announced the lineup of late-breaking clinical trials scheduled for presentation at Transcatheter Cardiovascular Therapeutics 2016 scientific symposium, to be held from Oct. 29 to Nov. 2 in Washington, D.C.

The CRF stated in a press release that 11 presentations were selected as late-breakers, including:

• ILUMIEN III (OPTIMIZE PCI), a randomized trial of patients with CAD undergoing stent implantation guided by optimal coherence tomography, IVUS or angiography.
• BIO-RESORT (TWENTE III), a three-arm study of two biodegradable polymer-based drug-eluting stents and durable polymer DES in an all-comers population with CAD.
• BIONICS, a comparison of a ridaforolimus-eluting stent vs. a zotarolimus-eluting stent in patients with CAD.
• EXCEL, which is comparing CABG vs. everolimus-eluting stents in patients with left main CAD.
• NOBLE, which is comparing CABG vs. biolimus-eluting stents in patients with left main CAD.
• SENTINEL, in which cerebral protection is evaluated in patients with severe aortic stenosis undergoing TAVR.
• PARTNER II QUALITY OF LIFE, an assessment of health status benefits from a trial comparing TAVR with surgical aortic valve replacement in patients with severe aortic stenosis at intermediate risk for surgery.
• PARTNER I FIVE-YEAR ECHO, an investigation of long-term hemodynamic and structural outcomes of TAVR in patients at high risk for surgery or considered inoperable.

• ILLUMENATE U.S., a trial comparing a paclitaxel-coated balloon with an uncoated balloon for treatment of femoropopliteal artery disease.
• Watchman U.S. post-approval study: a presentation of results from a registry of patients with atrial fibrillation requiring stroke prevention treated with a left atrial appendage closure device (Watchman, Boston Scientific).
• Amulet observational study: a prospective observational study of patients with AF treated with a left atrial appendage closure device (Amplatzer Amulet, St. Jude Medical) for stroke prevention.

The CRF also announced 16 first report investigations that will be presented.

Cardiology Today and Cardiology Today’s Intervention will report live from the sessions. Visit Healio.com/Cardiology during the sessions for breaking news, videos, perspective from experts in the field on major results and announcements, and more.